As part of the agreement, ImClone will utilize Champions Biotechnology’s Biomerk Tumorgrafts in the initial preclinical evaluation.
Doug Burkett, president of Champions Biotechnology, said: “Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies.”